Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Delayed Australian S.E. Other stock markets 06:55:31 15/07/2026 am IST			5-day change	1st Jan Change
0.0655 ^AUD	+2.34%		-0.76%	-22.94%

12/06	Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment	MT
27/05	Neurizon Therapeutics Limited Expands Regimen I of the Healey Als Platform Trial to 240 Participants	CI

Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%

Published on 05/13/2026 at 06:27 am IST

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Neurizon Therapeutics Limited

12/06	Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment	MT
27/05	Neurizon Therapeutics Limited Expands Regimen I of the Healey Als Platform Trial to 240 Participants	CI
13/05	Neurizon Therapeutics receives ethics approval for Phase 1 Nuz-001 oral liquid formulation study	RE
13/05	Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%	MT
08/05	Neurizon Therapeutics Limited Announces Board Changes, Effective May 8, 2026	CI
16/04	Neurizon Therapeutics Raises Nearly AU$3 Million to Reduce Entitlement Offer Shortfall; Shares Fall 7%	MT
16/04	Neurizon Therapeutics announces placement of entitlement offer shortfall to raise ~A$2.7 million	RE
01/04	Neurizon Therapeutics Says Preclinical Findings Show NUZ-001 Drug Candidate Raises Protein Clearance Activity in Neuronal Systems; Shares Rise 5%	MT
16/03	Neurizon Therapeutics says Michael Thurn resigns as managing director and CEO	RE
16/03	Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%	MT
05/03	Neurizon Says Pre-Clinical Data Supports Potential of Drug Candidate for Neurodegenerative Disease	MT
27/02	Neurizon Therapeutics Limited Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial	CI
25/02	Neurizon Therapeutics posts loss for half year attributable of A$5.5 million	RE
25/02	Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2025	CI
20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT

Chart Neurizon Therapeutics Limited

Duration

Period

NUZ: Dynamic Chart

Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.

Employees

Sector

Pharmaceuticals

More about the company